A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
NCT ID: NCT00251979
Last Updated: 2011-06-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1312 participants
INTERVENTIONAL
2005-10-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers
NCT01591083
High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
NCT01757275
Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients
NCT02456012
Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding
NCT00402259
The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESD
NCT02730533
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Esomeprazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* One endoscopically confirmed bleeding ulcer in the stomach or duodenum
Exclusion Criteria
* Major cardiovascular event.
* Severe hepatic disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Nexium Medical Sciences Director
Role: STUDY_DIRECTOR
AstraZeneca
Joseph Sung, MD
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Braunau/Inn, , Austria
Research Site
Feldbach, , Austria
Research Site
Graz, , Austria
Research Site
Krems, , Austria
Research Site
Vienna, , Austria
Research Site
Wels, , Austria
Research Site
Aalborg, , Denmark
Research Site
Amager, , Denmark
Research Site
Copenhagen, , Denmark
Research Site
Glostrup Municipality, , Denmark
Research Site
Holstebro, , Denmark
Research Site
Odense, , Denmark
Research Site
Randers, , Denmark
Research Site
Slagelse, , Denmark
Research Site
Helsinki, , Finland
Research Site
Kuopio, , Finland
Research Site
Amiens, , France
Research Site
Bordeaux, , France
Research Site
Clermont-Ferrand, , France
Research Site
Lille, , France
Research Site
Nice, , France
Research Site
Paris, , France
Research Site
Rouen, , France
Research Site
Berlin, , Germany
Research Site
Bochum, , Germany
Research Site
Celle, , Germany
Research Site
Dresden, , Germany
Research Site
Karlsruhe, , Germany
Research Site
Leipzig, , Germany
Research Site
Ludwigshafen, , Germany
Research Site
Magdeburg, , Germany
Research Site
Weimar, , Germany
Research Site
Athens, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Hong Kong, , Hong Kong
Research Site
Arnhem, , Netherlands
Research Site
Dordrecht, , Netherlands
Research Site
Hengelo, , Netherlands
Research Site
Nieuwegein, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Zwolle, , Netherlands
Research Site
Ålesund, , Norway
Research Site
Drammen, , Norway
Research Site
Kristiansand, , Norway
Research Site
Lorenskog, , Norway
Research Site
Oslo, , Norway
Research Site
Tønsberg, , Norway
Research Site
Bucharest, , Romania
Research Site
Craiova, , Romania
Research Site
Iași, , Romania
Research Site
Tg. Mures, , Romania
Research Site
Timișoara, , Romania
Research Site
Moscow, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Bloemfontein, , South Africa
Research Site
Cape Town, , South Africa
Research Site
Pietermaritzburg, , South Africa
Research Site
Barcelona, , Spain
Research Site
Madrid, , Spain
Research Site
Sabadell, , Spain
Research Site
Santiago, , Spain
Research Site
Gothenburg, , Sweden
Research Site
Karlstad, , Sweden
Research Site
Kristianstad, , Sweden
Research Site
Linköping, , Sweden
Research Site
Norrköping, , Sweden
Research Site
Östersund, , Sweden
Research Site
Skövde, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Sundsvall, , Sweden
Research Site
Trollhättan, , Sweden
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Bursa, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
İzmit, , Turkey (Türkiye)
Research Site
Birmingham, , United Kingdom
Research Site
Derby, , United Kingdom
Research Site
Leeds, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lau J, Lind T, Persson T, Eklund S. Effect of baseline characteristics on response to proton pump inhibitors in patients with peptic ulcer bleeding. J Dig Dis. 2017 Feb;18(2):99-106. doi: 10.1111/1751-2980.12447.
Kuipers EJ, Sung JJ, Barkun A, Mossner J, Jensen D, Stuart R, Lau JY, Ahlbom H, Lind T, Kilhamn J. Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther. 2011 Feb;28(2):150-9. doi: 10.1007/s12325-010-0095-5. Epub 2010 Dec 15.
Barkun AN, Adam V, Sung JJ, Kuipers EJ, Mossner J, Jensen D, Stuart R, Lau JY, Naucler E, Kilhamn J, Granstedt H, Liljas B, Lind T. Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics. 2010;28(3):217-30. doi: 10.2165/11531480-000000000-00000.
Sung JJ, Barkun A, Kuipers EJ, Mossner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T; Peptic Ulcer Bleed Study Group. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009 Apr 7;150(7):455-64. doi: 10.7326/0003-4819-150-7-200904070-00105. Epub 2009 Feb 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D961DC00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.